RT4 Orthotopic Mouse Model Service for Bladder Cancer

The RT4 orthotopic mouse model for bladder cancer provides a faithful luminal-papillary preclinical platform that recapitulates the native urothelial tumor microenvironment, including contact with urine and mechanical stress from bladder wall elasticity. Alfa Cytology delivers this specialized orthotopic model service with end-to-end technical support—from cell line authentication and surgical implantation to longitudinal tumor monitoring and comprehensive endpoint analysis—empowering researchers to advance their bladder cancer drug discovery programs with confidence.

Overview of RT4 Orthotopic Mouse Model for Bladder Cancer

The RT4 cell line was established in 1970 from explants of a recurring papillary tumor of the urinary bladder and has since become a cornerstone model for luminal-like bladder cancer research. Characterized by epithelial morphology and a low-grade (G1) transitional cell phenotype, RT4 represents the non-aggressive, papillary subtype of urothelial carcinoma. Molecular profiling classifies RT4 within the luminal cluster, exhibiting high expression of urothelial differentiation markers such as FOXA1, GATA3, and uroplakins, alongside low expression of basal markers including KRT5/6 and EGFR. The cell line carries an activating FGFR3-related signaling signature and RHOA mutation, features commonly associated with luminal-papillary bladder tumors. In orthotopic settings, RT4 tumors establish within the bladder wall of immunodeficient hosts, exhibiting a superficial growth pattern that closely mirrors non-muscle invasive bladder cancer (NMIBC) biology.

Fig 1. Standardized surgical procedure for orthotopic transplantation of human bladder cancer (including RT4). (Lorenzatti Hiles, Guadalupe, et al., 2019)

Compared with subcutaneous xenografts, the orthotopic implantation of RT4 cells into the bladder preserves organ-specific tumor-stroma interactions, exposure to urinary components, and the mechanical environment of the urothelium. These physiological cues influence drug penetration, metabolic activity, and therapeutic response in ways that flank models cannot replicate. Consequently, the RT4 orthotopic model is particularly suited for preclinical evaluation of intravesical agents, FGFR-targeted therapies, and combination regimens designed for luminal-papillary bladder cancer.

Cell Line Information: RT4

The following table summarizes the essential characteristics of the RT4 human bladder cancer cell line, providing researchers with a comprehensive reference for model selection and experimental design.

Our Services

Alfa Cytology offers a comprehensive RT4 orthotopic mouse model service tailored to your preclinical research objectives, encompassing model establishment, in-life monitoring, pharmacodynamic analysis, and histopathological endpoints. Our experienced team ensures rigorous quality control, reproducible tumor growth, and seamless integration with downstream efficacy and safety assessments, providing you with reliable data to advance your bladder cancer therapeutic pipeline.

Workflow of RT4 Orthotopic Mouse Model Construction

The construction of the RT4 orthotopic bladder cancer model follows a standardized, quality-controlled workflow designed to ensure consistent tumor engraftment, robust growth kinetics, and reliable pharmacological readouts. Each stage is executed under strict ethical and scientific standards to deliver publication-ready preclinical data.

1. Cell Line Authentication and Expansion: RT4 cells are authenticated via STR profiling and expanded under optimized culture conditions to ensure genetic stability and viability prior to surgical implantation.
2. Host Selection and Preparation: Immunodeficient hosts—typically female athymic nude mice or NSG mice—are acclimatized and health-screened to minimize environmental variability and ensure engraftment success.
3. Anesthesia and Surgical Preparation: Mice are anesthetized using isoflurane or ketamine/xylazine cocktail. The lower abdomen is shaved, disinfected, and the bladder is manually emptied prior to exteriorization.
4. Bladder Wall Cell Injection: A midline laparotomy is performed to exteriorize the bladder dome. A suspension of 2.5–5 × 10⁵ viable RT4 cells in PBS is slowly injected into the ventral bladder wall using a 27–31 gauge needle, avoiding the ureteral orifices to prevent early urinary obstruction.
5. Surgical Closure and Recovery: The bladder is returned to the abdominal cavity, and the incision is closed with layered sutures. Mice are placed on a heated recovery pad and monitored until full mobility is regained.
6. Tumor Monitoring and Randomization: Tumor establishment and growth are monitored weekly via small-animal MRI, ultrasonography, or bioluminescence imaging; once tumors reach the target threshold, animals are randomized into treatment cohorts.
7. Treatment Administration and In-Life Assessment: Test compounds are administered according to the predefined dosing regimen, with concurrent monitoring of body weight, clinical signs, and tumor dimensions to evaluate tolerability and early efficacy signals.
8. Endpoint Analysis and Sample Collection: At study termination, tumors are excised, weighed, and processed for histopathology, immunohistochemistry, RNA sequencing, and biomarker analysis to generate comprehensive pharmacodynamic profiles.
9. Data Compilation and Reporting: All raw data, statistical analyses, and representative images are compiled into a structured study report, including tumor growth inhibition metrics, survival curves, and mechanistic insights for regulatory or publication use.

Fig 2. RT4 Orthotopic Mouse Model construction workflow.

Case Study-RT4 Orthotopic Mouse Model Development

In a representative preclinical engagement, the RT4 orthotopic bladder cancer model was successfully established in immunodeficient mice with a tumor take rate exceeding 80% and consistent growth kinetics suitable for multi-week efficacy studies. Treatment arms evaluating novel FGFR inhibitors and intravesical combination regimens demonstrated dose-dependent tumor growth inhibition, with select cohorts achieving significant tumor stasis compared to vehicle controls. Comprehensive pharmacodynamic analyses—including immunohistochemical assessment of proliferation markers, FGFR pathway modulation, and urothelial differentiation marker profiling—provided mechanistic validation of target engagement. Detailed quantitative results, including tumor volume trajectories, body weight profiles, and biomarker data, are available upon request; please contact our scientific team to discuss specific study parameters and customize the model to your therapeutic program.

Why Choose Alfa Cytology?

Alfa Cytology combines scientific rigor with operational flexibility to deliver high-quality RT4 orthotopic model services that meet the exacting standards of modern preclinical oncology research.

• Deep expertise with luminal-papillary bladder cancer models and established SOPs for reproducible RT4 orthotopic tumor engraftment.
• Comprehensive in-house capabilities spanning model construction, in-life management, bioanalysis, histopathology, and molecular profiling.
• Customizable study designs accommodating single-agent, combination, dose-escalation, and biomarker-driven endpoints tailored to your compound.
• Strict quality assurance including cell line authentication, health monitoring, and GLP-compliant data documentation for regulatory submissions.
• Dedicated project management ensuring transparent communication, milestone tracking, and rapid turnaround from study initiation to final report.
• Competitive pricing and flexible scheduling to accelerate your preclinical timeline without compromising scientific integrity.

Contact Us

If you are interested in leveraging the RT4 orthotopic mouse model for your bladder cancer preclinical research, we encourage you to reach out to us today. Our scientific team is ready to discuss your specific project requirements, provide detailed study proposals, and design a customized workflow that aligns with your therapeutic development goals. Contact us now to explore how Alfa Cytology can accelerate your preclinical bladder cancer program with reliable, high-quality orthotopic model services.

For research use only. Not intended for any clinical use.